Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation plus camrelizumab, cetuximab, and chemotherapy for RAS/BRAF wild-type MSS metastatic colorectal cancer
ChiCTR2200066100Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumabcetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2200066100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066100.